Study design for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
-
“randomized, controlled, open-label, adaptive, platform trial"
-
Primary outcome of interest: 28-day mortality (see "outcome" node for other outcomes)
-
Randomization and treatment: suspected or confirmed SARS-CoV-2 infection, randomly assigned DEX or control, followed for 28 days or until death/discharge (for more details see "randomization and treatment" child node)
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Study design for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Sample size and ending enrollment in evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Statistical analysis for evaluating 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
RECOVERY trial: a system for evaluating COVID-19 treatments
Learn After
Outcomes measured in 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial
Randomization and treatment in 28-day mortality and other clinical outcomes in a randomized controlled trial of Dexamethasone (DEX) among hospitalized COVID-19 patients in RECOVERY trial